You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (14) |
Back to Search
“Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis
- In: Poster presentation
- At: Buenos Aires (Argentina) (2016)
- Type: Poster
- Poster code: POS-HMIS-001
- By: ABRAHAM, Ivo (UNIVERSITY OF ARIZONA, Pharmacy Practice and Science, Tucson, United States)
- Co-author(s): Abdulaziz Alhossan:Center for Health Outcomes and PharmacoEconomic Research,UNIVERSITY OF ARIZONA,Tucson,United States;College of Pharmacy,King Saud University,Riyadh,Saudi Arabia|Chris Lee:School of Nursing and Medicine,Oregon Health & Science University,Portland ,United States|Karen MacDonald:,Matrix45,Tucson,United States|Ivo Abraham:Center for Health Outcomes and PharmacoEconomic Research,UNIVERSITY OF ARIZONA,Tucson,United States;,Matrix45,Tucson,United States;College of Pharmacy and College of Medicine,UNIVERSITY OF ARIZONA,Tucson,United States
- Abstract:
A total of 25 studies have evaluated the effectiveness of omalizumab under “real-life” conditions of heterogeneity in patients, clinicians, sites, and treatment patterns.
We searched PubMed and Embase for real-life studies on omalizumab in severe asthma published up to 2015. Three effect size types were extracted: single-point proportions; mean+SD
.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026